Bulletin & Website Upgrades
Changes are afoot in CLL Canada’s online presence, with a new format for our bulletin, an updated website and French language pages.
Read more
- E-Bulletin 32 – COVID-19 Protection, Immunoglobulin Therapy, A CLL Pioneer, Studies Recruiting CLL Patients.
- E-Bulletin 31 – When CLL Returns; COVID Vaccines, Vitamin D, Secondary Cancers, Clinical trials, A Role for FCR?
- E-Bulletin 30 – Pausing Ibrutinib? CLL Survival Rates, COVID Resource, I+V Treatment, Patient Input Opportunities, Journey to Recovery, Part 2
- E-Bulletin 29 – Journey to recovery, CLL survey, Zanubrutinib coming, can ChatGPT be trusted?, Paxlovid rebound, COVID update.
- E-Bulletin 28 – Advocating for the immune compromised, clinical trials, insect bites, webinar reviews, review of How Doctor’s Think
- E-Bulletin 27 – The Way Ahead as COVID Lingers On, COVID-19 Booster Recommended, Treatment Information and Guidance, ASH Highlights, Turning a CLL Diagnosis into Music.
- E-Bulletin 26 – Treatment issue : Ten-Year Retrospective, Choosing Between BTKi and BCL2i, Combinations, BCL2i Retreatment, CLL Canada News, PMPRB Regulations (again!)
- E-Bulletin 25 – COVID vaccination & treatments; Masks; CAR-T therapy; Immune deficiency; Inspire Health; Striking the balance; CLL Canada News; A CLL journey
- E-Bulletin 24 – Monoclonal antibody therapy and vaccines for COVID; Immunoglobulins and CLL progression; Treatment news; The BTK inhibitor story; A CLL journey.
- E-Bulletin 23 – On the end of COVID restrictions: the CLL patient’s dilemma. The risks of COVID and the effectiveness of vaccines in CLL patients. Things to think about when deciding whether to resume activities enjoyed before the pandemic.
- E-Bulletin 22 – Survey of members; Progress in reducing the delay to a second dose; Still no clarity on the efficacy of COVID vaccines in CLL patients; Canadian CLL Clinical Trials; Treatment news; Is there CLL research in Canada? A CLL journey